HONG KONG – The in vivo antileukemic efficacy and safety of a novel combination of apoptosis-regulating drugs seen in a recent study by Australian researchers suggests that inhibition of apoptosis and activation of another type of cell death, necroptosis, warrants clinical investigation as a treatment for acute myeloid leukemia (AML).